Does the media prefer TECX or AUPH?

In the previous week, Tectonic Therapeutic had 1 more articles in the media than Aurinia Pharmaceuticals. MarketBeat recorded 3 mentions for Tectonic Therapeutic and 2 mentions for Aurinia Pharmaceuticals. Aurinia Pharmaceuticals' average media sentiment score of 1.32 beat Tectonic Therapeutic's score of -0.25 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tectonic Therapeutic 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aurinia Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to NTLA or TECX?

In the previous week, Tectonic Therapeutic had 1 more articles in the media than Intellia Therapeutics. MarketBeat recorded 3 mentions for Tectonic Therapeutic and 2 mentions for Intellia Therapeutics. Intellia Therapeutics' average media sentiment score of 0.87 beat Tectonic Therapeutic's score of -0.25 indicating that Intellia Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Intellia Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tectonic Therapeutic 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor OCUL or TECX?

In the previous week, Ocular Therapeutix and Ocular Therapeutix both had 3 articles in the media. Ocular Therapeutix's average media sentiment score of 0.56 beat Tectonic Therapeutic's score of -0.25 indicating that Ocular Therapeutix is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ocular Therapeutix 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tectonic Therapeutic 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is IMNM or TECX more profitable?

Tectonic Therapeutic's return on equity of -32.33% beat Immunome's return on equity. Company Net Margins Return on Equity Return on Assets Immunome N/A -51.15% -47.32% Tectonic Therapeutic N/A -32.33% -30.92%

Does the media refer more to IMNM or TECX?

In the previous week, Immunome had 6 more articles in the media than Tectonic Therapeutic. MarketBeat recorded 9 mentions for Immunome and 3 mentions for Tectonic Therapeutic. Immunome's average media sentiment score of -0.12 beat Tectonic Therapeutic's score of -0.25 indicating that Immunome is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunome 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tectonic Therapeutic 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation and earnings, PHVS or TECX?

Pharvaris is trading at a lower price-to-earnings ratio than Tectonic Therapeutic, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pharvaris N/A N/A -$198.79M -$3.18 N/A Tectonic Therapeutic N/A N/A -$74.15M -$4.46 N/A

Is PHVS or TECX more profitable?

Tectonic Therapeutic's return on equity of -32.33% beat Pharvaris' return on equity. Company Net Margins Return on Equity Return on Assets Pharvaris N/A -67.56% -61.13% Tectonic Therapeutic N/A -32.33% -30.92%

Does the media favor PHVS or TECX?

In the previous week, Pharvaris had 9 more articles in the media than Tectonic Therapeutic. MarketBeat recorded 12 mentions for Pharvaris and 3 mentions for Tectonic Therapeutic. Tectonic Therapeutic's average media sentiment score of -0.25 beat Pharvaris' score of -0.44 indicating that Tectonic Therapeutic is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pharvaris 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tectonic Therapeutic 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Tectonic Therapeutic (TECX) Competitors

$37.93 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$37.87 -0.06 (-0.16%)

As of 07/2/2026 07:59 PM Eastern

Compare

TECX vs. AUPH, NTLA, OCUL, IMNM, and PHVS

Should you buy Tectonic Therapeutic stock or one of its competitors? MarketBeat compares Tectonic Therapeutic with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Tectonic Therapeutic include Aurinia Pharmaceuticals (AUPH), Intellia Therapeutics (NTLA), Ocular Therapeutix (OCUL), Immunome (IMNM), and Pharvaris (PHVS). These companies are all part of the "pharmaceutical products" industry.

How does Tectonic Therapeutic compare to Aurinia Pharmaceuticals?

Tectonic Therapeutic (NASDAQ:TECX) and Aurinia Pharmaceuticals (NASDAQ:AUPH) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, risk, analyst recommendations, institutional ownership, profitability, valuation and earnings.

Tectonic Therapeutic has a beta of 3.21, indicating that its share price is 221% more volatile than the broader market. Comparatively, Aurinia Pharmaceuticals has a beta of 1.41, indicating that its share price is 41% more volatile than the broader market.

62.6% of Tectonic Therapeutic shares are held by institutional investors. Comparatively, 36.8% of Aurinia Pharmaceuticals shares are held by institutional investors. 39.8% of Tectonic Therapeutic shares are held by insiders. Comparatively, 12.2% of Aurinia Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Aurinia Pharmaceuticals has higher revenue and earnings than Tectonic Therapeutic. Tectonic Therapeutic is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tectonic Therapeutic	N/A	N/A	-$74.15M	-$4.46	N/A
Aurinia Pharmaceuticals	$298.30M	6.73	$287.20M	$2.17	7.19

In the previous week, Tectonic Therapeutic had 1 more articles in the media than Aurinia Pharmaceuticals. MarketBeat recorded 3 mentions for Tectonic Therapeutic and 2 mentions for Aurinia Pharmaceuticals. Aurinia Pharmaceuticals' average media sentiment score of 1.32 beat Tectonic Therapeutic's score of -0.25 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tectonic Therapeutic	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aurinia Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aurinia Pharmaceuticals has a net margin of 99.97% compared to Tectonic Therapeutic's net margin of 0.00%. Aurinia Pharmaceuticals' return on equity of 26.62% beat Tectonic Therapeutic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tectonic Therapeutic	N/A	-32.33%	-30.92%
Aurinia Pharmaceuticals	99.97%	26.62%	19.65%

Tectonic Therapeutic presently has a consensus price target of $79.40, indicating a potential upside of 109.33%. Aurinia Pharmaceuticals has a consensus price target of $17.25, indicating a potential upside of 10.51%. Given Tectonic Therapeutic's stronger consensus rating and higher probable upside, research analysts plainly believe Tectonic Therapeutic is more favorable than Aurinia Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tectonic Therapeutic	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00
Aurinia Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.57

Summary

Tectonic Therapeutic and Aurinia Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does Tectonic Therapeutic compare to Intellia Therapeutics?

Intellia Therapeutics (NASDAQ:NTLA) and Tectonic Therapeutic (NASDAQ:TECX) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, analyst recommendations, dividends, profitability, valuation, risk and earnings.

Intellia Therapeutics has a beta of 1.77, meaning that its share price is 77% more volatile than the broader market. Comparatively, Tectonic Therapeutic has a beta of 3.21, meaning that its share price is 221% more volatile than the broader market.

Intellia Therapeutics currently has a consensus price target of $20.46, suggesting a potential upside of 16.49%. Tectonic Therapeutic has a consensus price target of $79.40, suggesting a potential upside of 109.33%. Given Tectonic Therapeutic's stronger consensus rating and higher possible upside, analysts clearly believe Tectonic Therapeutic is more favorable than Intellia Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intellia Therapeutics	3 Sell rating(s)	10 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.35
Tectonic Therapeutic	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00

Tectonic Therapeutic has a net margin of 0.00% compared to Intellia Therapeutics' net margin of -597.04%. Tectonic Therapeutic's return on equity of -32.33% beat Intellia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intellia Therapeutics	-597.04%	-57.47%	-46.24%
Tectonic Therapeutic	N/A	-32.33%	-30.92%

Tectonic Therapeutic has lower revenue, but higher earnings than Intellia Therapeutics. Tectonic Therapeutic is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intellia Therapeutics	$67.67M	36.26	-$412.69M	-$3.54	N/A
Tectonic Therapeutic	N/A	N/A	-$74.15M	-$4.46	N/A

88.8% of Intellia Therapeutics shares are held by institutional investors. Comparatively, 62.6% of Tectonic Therapeutic shares are held by institutional investors. 3.5% of Intellia Therapeutics shares are held by company insiders. Comparatively, 39.8% of Tectonic Therapeutic shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Tectonic Therapeutic had 1 more articles in the media than Intellia Therapeutics. MarketBeat recorded 3 mentions for Tectonic Therapeutic and 2 mentions for Intellia Therapeutics. Intellia Therapeutics' average media sentiment score of 0.87 beat Tectonic Therapeutic's score of -0.25 indicating that Intellia Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Intellia Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tectonic Therapeutic	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Tectonic Therapeutic beats Intellia Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Tectonic Therapeutic compare to Ocular Therapeutix?

Ocular Therapeutix (NASDAQ:OCUL) and Tectonic Therapeutic (NASDAQ:TECX) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, earnings, media sentiment, dividends, valuation and profitability.

In the previous week, Ocular Therapeutix and Ocular Therapeutix both had 3 articles in the media. Ocular Therapeutix's average media sentiment score of 0.56 beat Tectonic Therapeutic's score of -0.25 indicating that Ocular Therapeutix is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ocular Therapeutix	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tectonic Therapeutic	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Ocular Therapeutix presently has a consensus target price of $25.11, suggesting a potential upside of 160.49%. Tectonic Therapeutic has a consensus target price of $79.40, suggesting a potential upside of 109.33%. Given Ocular Therapeutix's higher possible upside, equities research analysts plainly believe Ocular Therapeutix is more favorable than Tectonic Therapeutic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocular Therapeutix	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79
Tectonic Therapeutic	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00

Tectonic Therapeutic has lower revenue, but higher earnings than Ocular Therapeutix. Tectonic Therapeutic is trading at a lower price-to-earnings ratio than Ocular Therapeutix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocular Therapeutix	$52.04M	40.56	-$265.94M	-$1.46	N/A
Tectonic Therapeutic	N/A	N/A	-$74.15M	-$4.46	N/A

Tectonic Therapeutic has a net margin of 0.00% compared to Ocular Therapeutix's net margin of -558.24%. Tectonic Therapeutic's return on equity of -32.33% beat Ocular Therapeutix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ocular Therapeutix	-558.24%	-64.28%	-48.15%
Tectonic Therapeutic	N/A	-32.33%	-30.92%

Ocular Therapeutix has a beta of 0.88, indicating that its stock price is 12% less volatile than the broader market. Comparatively, Tectonic Therapeutic has a beta of 3.21, indicating that its stock price is 221% more volatile than the broader market.

59.2% of Ocular Therapeutix shares are held by institutional investors. Comparatively, 62.6% of Tectonic Therapeutic shares are held by institutional investors. 3.1% of Ocular Therapeutix shares are held by insiders. Comparatively, 39.8% of Tectonic Therapeutic shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Tectonic Therapeutic beats Ocular Therapeutix on 9 of the 15 factors compared between the two stocks.

How does Tectonic Therapeutic compare to Immunome?

Immunome (NASDAQ:IMNM) and Tectonic Therapeutic (NASDAQ:TECX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, institutional ownership, analyst recommendations, risk, earnings and profitability.

Tectonic Therapeutic has lower revenue, but higher earnings than Immunome. Immunome is trading at a lower price-to-earnings ratio than Tectonic Therapeutic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunome	$6.94M	385.28	-$212.39M	-$2.38	N/A
Tectonic Therapeutic	N/A	N/A	-$74.15M	-$4.46	N/A

Tectonic Therapeutic's return on equity of -32.33% beat Immunome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunome	N/A	-51.15%	-47.32%
Tectonic Therapeutic	N/A	-32.33%	-30.92%

Immunome currently has a consensus price target of $33.17, suggesting a potential upside of 40.48%. Tectonic Therapeutic has a consensus price target of $79.40, suggesting a potential upside of 109.33%. Given Tectonic Therapeutic's stronger consensus rating and higher probable upside, analysts plainly believe Tectonic Therapeutic is more favorable than Immunome.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunome	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
Tectonic Therapeutic	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00

44.6% of Immunome shares are held by institutional investors. Comparatively, 62.6% of Tectonic Therapeutic shares are held by institutional investors. 7.2% of Immunome shares are held by company insiders. Comparatively, 39.8% of Tectonic Therapeutic shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Immunome has a beta of 2.07, indicating that its share price is 107% more volatile than the broader market. Comparatively, Tectonic Therapeutic has a beta of 3.21, indicating that its share price is 221% more volatile than the broader market.

In the previous week, Immunome had 6 more articles in the media than Tectonic Therapeutic. MarketBeat recorded 9 mentions for Immunome and 3 mentions for Tectonic Therapeutic. Immunome's average media sentiment score of -0.12 beat Tectonic Therapeutic's score of -0.25 indicating that Immunome is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunome	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tectonic Therapeutic	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Tectonic Therapeutic beats Immunome on 10 of the 15 factors compared between the two stocks.

How does Tectonic Therapeutic compare to Pharvaris?

Pharvaris (NASDAQ:PHVS) and Tectonic Therapeutic (NASDAQ:TECX) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, dividends, media sentiment, institutional ownership and risk.

Pharvaris currently has a consensus target price of $49.64, suggesting a potential upside of 46.59%. Tectonic Therapeutic has a consensus target price of $79.40, suggesting a potential upside of 109.33%. Given Tectonic Therapeutic's stronger consensus rating and higher probable upside, analysts clearly believe Tectonic Therapeutic is more favorable than Pharvaris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharvaris	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Tectonic Therapeutic	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00

Tectonic Therapeutic's return on equity of -32.33% beat Pharvaris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pharvaris	N/A	-67.56%	-61.13%
Tectonic Therapeutic	N/A	-32.33%	-30.92%

62.6% of Tectonic Therapeutic shares are owned by institutional investors. 11.8% of Pharvaris shares are owned by insiders. Comparatively, 39.8% of Tectonic Therapeutic shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Pharvaris is trading at a lower price-to-earnings ratio than Tectonic Therapeutic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharvaris	N/A	N/A	-$198.79M	-$3.18	N/A
Tectonic Therapeutic	N/A	N/A	-$74.15M	-$4.46	N/A

Pharvaris has a beta of -2.34, suggesting that its stock price is 334% less volatile than the broader market. Comparatively, Tectonic Therapeutic has a beta of 3.21, suggesting that its stock price is 221% more volatile than the broader market.

In the previous week, Pharvaris had 9 more articles in the media than Tectonic Therapeutic. MarketBeat recorded 12 mentions for Pharvaris and 3 mentions for Tectonic Therapeutic. Tectonic Therapeutic's average media sentiment score of -0.25 beat Pharvaris' score of -0.44 indicating that Tectonic Therapeutic is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pharvaris	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tectonic Therapeutic	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Tectonic Therapeutic beats Pharvaris on 11 of the 14 factors compared between the two stocks.

Get Tectonic Therapeutic News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TECX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TECX vs. The Competition

Export

Metric	Tectonic Therapeutic	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$715.70M	$3.78B	$7.18B	$12.48B
Dividend Yield	N/A	2.16%	2.66%	6.51%
P/E Ratio	-8.50	21.61	28.02	24.70
Price / Sales	N/A	331.74	535.36	97.93
Price / Cash	N/A	147.12	49.26	57.09
Price / Book	2.82	8.66	10.96	6.46
Net Income	-$74.15M	$23.81M	$3.57B	$337.01M
7 Day Performance	18.57%	3.39%	2.12%	1.69%
1 Month Performance	30.79%	10.81%	5.25%	3.81%
1 Year Performance	74.43%	62.61%	33.29%	23.90%

Tectonic Therapeutic Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TECX Tectonic Therapeutic	2.8621 of 5 stars	$37.93 flat	$79.40 +109.3%	+74.4%	$715.70M	N/A	N/A	120	News Coverage Gap Down High Trading Volume
AUPH Aurinia Pharmaceuticals	3.0595 of 5 stars	$17.88 +2.0%	$17.25 -3.5%	+106.3%	$2.25B	$283.05M	8.24	300	Positive News Gap Up
NTLA Intellia Therapeutics	2.341 of 5 stars	$15.25 -3.2%	$20.46 +34.1%	+63.9%	$2.20B	$67.67M	N/A	600
OCUL Ocular Therapeutix	3.0798 of 5 stars	$10.11 +1.4%	$24.89 +146.2%	+3.0%	$2.18B	$51.95M	N/A	230
IMNM Immunome	2.9988 of 5 stars	$19.33 +0.8%	$33.17 +71.6%	+171.1%	$2.17B	$6.94M	N/A	40	News Coverage Insider Trade Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TECX) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tectonic Therapeutic (TECX) Competitors

TECX vs. AUPH, NTLA, OCUL, IMNM, and PHVS

How does Tectonic Therapeutic compare to Aurinia Pharmaceuticals?

Summary

How does Tectonic Therapeutic compare to Intellia Therapeutics?

Summary

How does Tectonic Therapeutic compare to Ocular Therapeutix?

Summary

How does Tectonic Therapeutic compare to Immunome?

Summary

How does Tectonic Therapeutic compare to Pharvaris?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TECX vs. The Competition

Tectonic Therapeutic Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tectonic Therapeutic (TECX) Competitors

TECX vs. AUPH, NTLA, OCUL, IMNM, and PHVS

How does Tectonic Therapeutic compare to Aurinia Pharmaceuticals?

Which has more volatility & risk, TECX or AUPH?

Do institutionals and insiders have more ownership in TECX or AUPH?

Which has stronger earnings & valuation, TECX or AUPH?

Does the media prefer TECX or AUPH?

Is TECX or AUPH more profitable?

Do analysts prefer TECX or AUPH?

Summary

How does Tectonic Therapeutic compare to Intellia Therapeutics?

Which has more volatility and risk, NTLA or TECX?

Do analysts prefer NTLA or TECX?

Is NTLA or TECX more profitable?

Which has preferable earnings & valuation, NTLA or TECX?

Do institutionals & insiders believe in NTLA or TECX?

Does the media refer more to NTLA or TECX?

Summary

How does Tectonic Therapeutic compare to Ocular Therapeutix?

Does the media favor OCUL or TECX?

Do analysts rate OCUL or TECX?

Which has preferable valuation and earnings, OCUL or TECX?

Is OCUL or TECX more profitable?

Which has more risk and volatility, OCUL or TECX?

Do insiders & institutionals believe in OCUL or TECX?

Summary

How does Tectonic Therapeutic compare to Immunome?

Which has stronger earnings & valuation, IMNM or TECX?

Is IMNM or TECX more profitable?

Do analysts recommend IMNM or TECX?

Do insiders and institutionals believe in IMNM or TECX?

Which has more risk & volatility, IMNM or TECX?

Does the media refer more to IMNM or TECX?

Summary

How does Tectonic Therapeutic compare to Pharvaris?

Do analysts prefer PHVS or TECX?

Is PHVS or TECX more profitable?

Do insiders & institutionals hold more shares of PHVS or TECX?

Which has better valuation and earnings, PHVS or TECX?

Which has more volatility and risk, PHVS or TECX?

Does the media favor PHVS or TECX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TECX vs. The Competition

Tectonic Therapeutic Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools